Immunotherapeutic Efficacy of Recombinant Mycobacterium Smegmatis Expressing Ag85B-ESAT6 Fusion Protein Against Persistent Tuberculosis Infection in Mice

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2013 Aug 29

PMID 23982126

Citations 8

Authors

Ping Wang

Limei Wang

Wei Zhang

Yinlan Bai

Jian Kang

Yanfei Hao

Tailai Luo

Changhong Shi

Zhikai Xu

Affiliations

Soon will be listed here.

Abstract

The application of immunotherapy in combination with chemotherapy is considered an effective treatment strategy against persistent Mycobacterium tuberculosis (Mtb) infection. In this study, we constructed a novel recombinant Mycobacterium smegmatis (rMS) strain that expresses Ag85B and ESAT6 fusion protein (AE-rMS). Immunization of C57BL/6 mice with AE-rMS generated mainly Th1-type immune responses by strongly stimulating IFN-γ- and IL-2-producing splenocytes and increasing antigen-specific cytotoxic T lymphocyte (CTL) activity. To test the immunotherapeutic efficacy of AE-rMS, a persistent tuberculosis infection (PTBI) model was established via tail-vein injection of C57BL/6 mice with 1×10(4) colony forming units (CFU) of Mtb strain H37Rv in combination with concurrent chemotherapy drugs isoniazid (INH) and pyrazinamide (PZA). PTBI mice immunized with AE-rMS showed high levels of IFN-γ secreted by splenocytes and decreased bacteria loads in lung. Treatment with only the anti-tuberculosis (anti-TB) drugs RFP and INH (RI), decreased bacteria loads to low levels, with the Th1-type immune response further attenuated. Moreover, AE-rMS, when combined with RI treatment, further reduced the bacteria load as well as the pathological tissue damage in lung. Together, these results demonstrated the essential roles of AE-rMS-induced Th1-type responses, providing an effective treatment strategy by combining AE-rMS and RI for persistent TB.

Citing Articles

Ag85B with c-di-AMP as mucosal adjuvant showed immunotherapeutic effects on persistent Mycobacterium tuberculosis infection in mice.

Liang X, Cui R, Li X, Ning H, Kang J, Lu Y Braz J Med Biol Res. 2024; 57:e13409.

PMID: 38958367 PMC: 11221865. DOI: 10.1590/1414-431X2024e13409.

, a Promising Vaccine Vector for Preventing TB and Other Diseases: Vaccinomics Insights and Applications.

Xie W, Wang L, Luo D, Soni V, Rosenn E, Wang Z Vaccines (Basel). 2023; 11(8).

PMID: 37631870 PMC: 10459588. DOI: 10.3390/vaccines11081302.

CTLs: Killers of intracellular bacteria.

Tian L, Zhou W, Wu X, Hu Z, Qiu L, Zhang H Front Cell Infect Microbiol. 2022; 12:967679.

PMID: 36389159 PMC: 9645434. DOI: 10.3389/fcimb.2022.967679.

c-di-AMP Accumulation Regulates Growth, Metabolism, and Immunogenicity of .

Ning H, Liang X, Xie Y, Bai L, Zhang W, Wang L Front Microbiol. 2022; 13:865045.

PMID: 35685938 PMC: 9171234. DOI: 10.3389/fmicb.2022.865045.

The Effect of Delivery Systems on the Induction of T Helper 1 Cell Response to an ESAT6-Like Protein Rv3619c and Identification of Its Immunodominant Peptides.

Safar H, Mustafa A, Amoudy H, El-Hashim A Med Princ Pract. 2022; 31(4):359-367.

PMID: 35584661 PMC: 9485963. DOI: 10.1159/000525136.

References

Wang R, Marcotte E . The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways. J Proteome Res. 2008; 7(3):855-65. DOI: 10.1021/pr0703066. View

Goldstone R, Moreland N, Bashiri G, Baker E, Lott J . A new Gateway vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis. Protein Expr Purif. 2007; 57(1):81-7. DOI: 10.1016/j.pep.2007.08.015. View

Post F, Manca C, Neyrolles O, Ryffel B, Young D, Kaplan G . Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced cytokine production by human macrophages in vitro. Infect Immun. 2001; 69(3):1433-9. PMC: 98038. DOI: 10.1128/IAI.69.3.1433-1439.2001. View

Cooper A, Khader S . The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2009; 226:191-204. PMC: 4298252. DOI: 10.1111/j.1600-065X.2008.00702.x. View

Yi Z, Fu Y, Yang C, Li J, Luo X, Chen Q . Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice. Vaccine. 2006; 25(4):638-48. DOI: 10.1016/j.vaccine.2006.08.037. View

Silva C, Bonato V, Coelho-Castelo A, De Souza A, Santos S, Lima K . Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther. 2004; 12(3):281-7. DOI: 10.1038/sj.gt.3302418. View

Weinrich Olsen A, van Pinxteren L, Meng Okkels L, Birk Rasmussen P, Andersen P . Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun. 2001; 69(5):2773-8. PMC: 98224. DOI: 10.1128/IAI.69.5.2773-2778.2001. View

Kaufmann S, Gengenbacher M . Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol. 2012; 23(6):900-7. DOI: 10.1016/j.copbio.2012.03.007. View

Yu D, Hu X, Cai H . Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther. 2008; 15(9):652-9. DOI: 10.1038/gt.2008.13. View

10.

Andersen P . The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology. 1994; 191(4-5):537-47. DOI: 10.1016/S0171-2985(11)80460-2. View

11.

Yang X, Chen Q, Li Y, Wu S . Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One. 2011; 6(9):e23826. PMC: 3167806. DOI: 10.1371/journal.pone.0023826. View

12.

Aagaard C, Hoang T, Dietrich J, Cardona P, Izzo A, Dolganov G . A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011; 17(2):189-94. DOI: 10.1038/nm.2285. View

13.

Shao Y, Yang D, Xu W, Lu W, Song H, Dai Y . Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead. BMC Public Health. 2011; 11:110. PMC: 3045946. DOI: 10.1186/1471-2458-11-110. View

14.

Altaf M, Miller C, Bellows D, OToole R . Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb). 2010; 90(6):333-7. DOI: 10.1016/j.tube.2010.09.002. View

15.

Anderson E, Webb E, Mawa P, Kizza M, Lyadda N, Nampijja M . The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine. 2012; 30(12):2083-9. PMC: 3314967. DOI: 10.1016/j.vaccine.2012.01.053. View

16.

Zhao S, Zhao Y, Mao F, Zhang C, Bai B, Zhang H . Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS One. 2012; 7(2):e31908. PMC: 3283714. DOI: 10.1371/journal.pone.0031908. View

17.

Yang C, He Y, Zhang L, Xu L, Yi Z, Wang Y . GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine. Int J Tuberc Lung Dis. 2009; 13(11):1360-6. View

18.

Cayabyab M, Hovav A, Hsu T, Krivulka G, Lifton M, Gorgone D . Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol. 2006; 80(4):1645-52. PMC: 1367151. DOI: 10.1128/JVI.80.4.1645-1652.2006. View

19.

Uhlin M, Andersson J, Zumla A, Maeurer M . Adjunct immunotherapies for tuberculosis. J Infect Dis. 2012; 205 Suppl 2:S325-34. DOI: 10.1093/infdis/jis197. View

20.

Hernandez-Pando R, Aguilar D, Orozco H, Cortez Y, Rosa Brunet L, Rook G . Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in BALB/c mice with pulmonary tuberculosis. Clin Vaccine Immunol. 2008; 15(11):1730-6. PMC: 2583530. DOI: 10.1128/CVI.00286-08. View